{
  "trial_id": "NCT03434262",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Participants with recurrent, progressive, or refractory brain tumors.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age \u2265 1 year and < 25 years at the time of screening.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participants and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Evaluable disease, as defined as meeting any of the following:",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to study enrollment with no plans for escalation.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Participants must discontinue herbal preparations, herbal medication, and dietary supplements, with the exception of multivitamins, at least 7 days prior to study enrollment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participants must have a Lansky (\u2264 16 years) or Karnofsky (> 16 years) score of at least 50 and, in the opinion of the investigator, a minimum life expectancy of at least 6 weeks at the time of study enrollment.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Participant must have adequate bone marrow and organ function defined as:",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Participants with a diagnosis of recurrent, progressive, or refractory low grade glioma (LGG).",
      "label": "triggers",
      "evidence": "quote"
    },
    {
      "criterion": "Previous exposure to a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib).",
      "label": "triggers",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has a history of anaplastic astrocytoma and is receiving corticosteroids. However, the patient's last dose of anticancer therapy was received more than 4 weeks prior to study enrollment.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT03434262",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}